Nice, France - Shanghai MicroPort EP MedTech Co ("MicroPort® EP") recently attended the 20th CARDIOSTIM-EHRA EUROPACE ("CARDIOSTIM-EHRA EUROPACE 2016") to promote its in-house developed Columbus® 3D EP Navigation System ("Columbus®").
The CARDIOSTIM-EHRA EUROPACE is a world congress in cardiac electrophysiology and cardiac techniques, and this year it covers various sectors including cardiac pacing, cardiac failure, cardiomyopathy, cardiac resynchronization therapy and cardiac electrophysiology, with focus on new technologies like wireless pacemaker, subcutaneous ICD, radiofrequency ablation navigation system, ablation of ventricular tachycardia/ventricular flutter, discussed by clinical and technical specialists from all over the world.
Displayed in the MicroPort® EP booth, Columbus® and its matching catheter drew attention from professionals in attendance. French cardiac electrophysiologist Michel Haïssaguerre, Professor at the Hôpital Cardiologique du Haut–Lévèque, who is best known for his remarkable contributions in the area of atrial fibrillation ablation, tried operating FireMagic® 3D Irrigated Ablation Catheter ("FireMagic®") that Columbus® works with. He said, he expected to see more China-developed innovative medical devices appear on the world stage. Many domestic and international electrophysiological experts and scholars, including Director Guofang Cao of Center for Medical Device Evaluation of China Food and Drug Administration ("CFDA"), visited the MicroPort® EP booth, communicated with President of MicroPort® EP Dr. Yiyong Sun, and offered their opinions and suggestions on the future development of the radiofrequency ablation treatment.
Columbus® and FireMagic® are mainly used in the treatment for drug resistant atrial fibrillation. When used together, they show the real-time location and moving direction of the catheter tip in cardiac chambers, which improves the success rate of the operation while reducing X-ray exposure to physicians. The two products obtained the CE Mark in 2013, and have been used in countries including Dominica, Greece, Turkey and Spain. In 2016, they gained CFDA approval, and Columbus® was the first interventional medical device granted by CFDA the Green Channel status, a special fast-track procedure for innovative medical devices to gain CFDA approval. Columbus® combined with FireMagic® was listed under the National High-tech R&D Program (863 Program) and the National Key Technology Support Program. With both of them officially launched in the China market, MicroPort® EP provides a comprehensive solution to domestic patients with complex arrhythmias.